1 day+0.19%
Current year+3.00%
Current year 0.09
Extreme 0.09
0.11
1 year 0.09
Extreme 0.09
1.5
3 years 0.09
Extreme 0.09
10.62
5 years 0.09
Extreme 0.09
19.14
10 years 0.09
Extreme 0.09
57.39
Manager TitleAgeSince
President - 2026-02-02
Corporate Secretary - 2026-02-02
Corporate Officer/Principal - 2025-01-20
Director TitleAgeSince
Director/Board Member - 2026-02-02
Date Insider Type Main position Quantity % Market Cap. Importance
2/3/26 Issuer sale

Director

328,690 0.2278%
2/3/26 Issuer sale

Director

393,053 0.2724%
2/3/26 Issuer sale

Director

328,690 0.2278%
Change 5-day change 1-year change 3-year change Capi.($)
+0.19%-.--% - - 15.7M
+2.41%+0.29%+42.02%+71.57% 64.69B
-0.15%+7.50%+11.01%+73.48% 54.78B
+0.57%+4.60%+10.07%+92.86% 53.49B
+0.37%+4.67%+27.03%+52.07% 45.98B
-1.21%+2.32%+21.80%+123.81% 42.94B
-0.37%+5.07%+249.91%+918.74% 40.08B
+0.05%+0.21%+18.26%+58.53% 33.52B
-0.38%+5.68%+36.43%+27.54% 23.67B
+1.19%-4.98%+29.01%-0.65% 23.97B
Average +0.27%+2.41%+49.51%+157.55% 42.57B
Weighted average by Cap. +0.39%+2.73%+47.57%+158.58%
Logo Applied Therapeutics, Inc.
Applied Therapeutics, Inc. is a clinical-stage biopharmaceutical company engaged in the development of drug candidates against validated molecular targets in rare diseases. The Company’s lead drug candidate, govorestat, is a central nervous system penetrant Aldose Reductase Inhibitor (ARI) for the treatment of CNS rare metabolic diseases, including classic galactosemia, sorbitol dehydrogenase (SORD) deficiency and phosphomannomutase 2 (PMM2)-congenital disorder glycosylation (CDG). The Company is also developing AT-001, an investigational, ARI developed as an oral therapy for the treatment of diabetic cardiomyopathy (DbCM). It has completed a Phase I/II clinical trial evaluating AT-001 in approximately 120 patients with type II diabetes. The Company’s pipeline also includes AT-003, an ARI designed to cross through the back of the eye when dosed orally, and has demonstrated strong retinal penetrance, for the treatment of diabetic retinopathy (DR).
Employees
28
Trader
-
Investor
-
Global
-
Quality
-
ESG MSCI
BB
MarketScreener Ratings - Applied Therapeutics, Inc.
  1. Stock Market
  2. Stocks
  3. APLT Stock